Zymeworks (ZYME) Non-Current Assets (2021 - 2026)
Zymeworks (ZYME) posted Non-Current Assets of $92.5 million for Q1 2026, down 5.34% sequentially from $97.8 million in Q4 2025, and down 22.28% YoY from $119.1 million in Q1 2025.
Analysis
Zymeworks (ZYME) Non-Current Assets (2021 - 2026) Analysis & Trends
Zymeworks has reported Non-Current Assets for 6 years, with the latest figure at $92.5 million in Q1 2026.
- Quarterly Non-Current Assets fell 22.28% year-over-year to $92.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $408.1 million (down 26.76% YoY) and the FY2025 annual result came in at $97.8 million, down 39.89% from the prior year.
- Non-Current Assets retreated to $92.5 million in Q1 2026 per ZYME's latest filing, from $97.8 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $181.7 million in Q3 2023 and troughed at $92.5 million in Q1 2026.
- A 5-year average of $136.3 million and a median of $132.1 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2023 and 2025: Non-Current Assets jumped 65.8% in 2023, then sank 39.89% in 2025.
- Over 5 years, Non-Current Assets stood at $104.0 million in 2022, then soared by 61.46% to $168.0 million in 2023, then fell by 3.16% to $162.6 million in 2024, then tumbled by 39.89% to $97.8 million in 2025, then declined by 5.34% to $92.5 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $92.5 million, $97.8 million, and $105.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | 5.15 Bn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 294.93 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 1.96 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 938.60 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 18.06 Bn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 10 | Zymeworks | 2.13 Bn | 1.86 Bn | - | 98.58 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 98.58 Mn |
| Mar 31, 2026 | 92.54 Mn |
| Dec 31, 2025 | 97.76 Mn |
| Sep 30, 2025 | 105.56 Mn |
| Jun 30, 2025 | 112.26 Mn |
| Mar 31, 2025 | 119.06 Mn |
| Dec 31, 2024 | 162.64 Mn |
| Sep 30, 2024 | 143.38 Mn |
| Jun 30, 2024 | 132.14 Mn |
| Mar 31, 2024 | 159.93 Mn |
| Dec 31, 2023 | 167.95 Mn |
| Sep 30, 2023 | 181.73 Mn |
| Jun 30, 2023 | 181.72 Mn |
| Mar 31, 2023 | 174.37 Mn |
| Dec 31, 2022 | 104.02 Mn |
| Sep 30, 2022 | 109.61 Mn |
| Dec 31, 2021 | 100.91 Mn |